FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000535235> ?p ?o ?g. }

• W2000535235 endingPage "560" @default.
• W2000535235 startingPage "549" @default.
• W2000535235 abstract "Tegaserod (Zelnorm®) is a potent 5‐hydroxytryptamine 4 (5‐HT 4 ) receptor agonist with clinical efficacy in disorders associated with reduced gastrointestinal motility and transit. The present study investigated the interaction of tegaserod with 5‐HT 2 receptors, and compared its potency in this respect to its 5‐HT 4 receptor agonist activity. Tegaserod had significant binding affinity for human recombinant 5‐HT 2A , 5‐HT 2B and 5‐HT 2C receptors (p K i =7.5, 8.4 and 7.0, respectively). The 5‐HT 2B receptor‐binding affinity of tegaserod was identical to that at human recombinant 5‐HT 4(c) receptors (mean p K i =8.4) in human embryonic kidney‐293 (HEK‐293) cells stably transfected with the human 5‐HT 4(c) receptor. Tegaserod (0.1–3 μ M ) inhibited 5‐HT‐mediated contraction of the rat isolated stomach fundus potently (p A 2 =8.3), consistent with 5‐HT 2B receptor antagonist activity. Tegaserod produced, with similar potency, an elevation of adenosine 3′,5′ cyclic monophosphate in HEK‐293 cells stably transfected with the human 5‐HT 4(c) receptor (mean pEC 50 =8.6), as well as 5‐HT 4 receptor‐mediated relaxation of the rat isolated oesophagus (mean pEC 50 =8.2) and contraction of the guinea‐pig isolated colon (mean pEC 50 =8.3). Following subcutaneous administration, tegaserod (0.3 or 1 mg kg −1 ) inhibited contractions of the stomach fundus in anaesthetized rats in response to intravenous dosing of α ‐methyl 5‐HT (0.03 mg kg −1 ) and BW 723C86 (0.3 mg kg −1 ), selective 5‐HT 2B receptor agonists. At similar doses, tegaserod (1 and 3 mg kg −1 subcutaneously) evoked a 5‐HT 4 receptor‐mediated increase in colonic transit in conscious guinea‐pigs. The data from this study indicate that tegaserod antagonizes 5‐HT 2B receptors at concentrations similar to those that activate 5‐HT 4 receptors. It remains to be determined whether this 5‐HT 2B receptor antagonist activity of tegaserod contributes to its clinical profile. British Journal of Pharmacology (2004) 143 , 549–560. doi: 10.1038/sj.bjp.0705929" @default.
• W2000535235 created "2016-06-24" @default.
• W2000535235 creator A5008117910 @default.
• W2000535235 creator A5010423079 @default.
• W2000535235 creator A5013867167 @default.
• W2000535235 creator A5018967713 @default.
• W2000535235 creator A5027330002 @default.
• W2000535235 creator A5041298768 @default.
• W2000535235 creator A5057624684 @default.
• W2000535235 creator A5062317656 @default.
• W2000535235 creator A5066889736 @default.
• W2000535235 creator A5083508865 @default.
• W2000535235 creator A5091808052 @default.
• W2000535235 date "2004-11-01" @default.
• W2000535235 modified "2023-10-15" @default.
• W2000535235 title "The 5-HT₄ receptor agonist, tegaserod, is a potent 5-HT_2B receptor antagonist <i>in vitro</i> and <i>in vivo</i>" @default.
• W2000535235 cites W1595141034 @default.
• W2000535235 cites W1982805508 @default.
• W2000535235 cites W1987658414 @default.
• W2000535235 cites W1991685675 @default.
• W2000535235 cites W2004522200 @default.
• W2000535235 cites W2008830399 @default.
• W2000535235 cites W2013494536 @default.
• W2000535235 cites W2017702415 @default.
• W2000535235 cites W2019214891 @default.
• W2000535235 cites W2019834328 @default.
• W2000535235 cites W2021834168 @default.
• W2000535235 cites W2022142957 @default.
• W2000535235 cites W2024952531 @default.
• W2000535235 cites W2036987718 @default.
• W2000535235 cites W2037676171 @default.
• W2000535235 cites W2039892245 @default.
• W2000535235 cites W2053074524 @default.
• W2000535235 cites W2057971042 @default.
• W2000535235 cites W2063899722 @default.
• W2000535235 cites W2066900142 @default.
• W2000535235 cites W2071327709 @default.
• W2000535235 cites W2071902429 @default.
• W2000535235 cites W2074631079 @default.
• W2000535235 cites W2075434858 @default.
• W2000535235 cites W2079825367 @default.
• W2000535235 cites W2094709583 @default.
• W2000535235 cites W2094719038 @default.
• W2000535235 cites W2095131733 @default.
• W2000535235 cites W2106985819 @default.
• W2000535235 cites W2107308107 @default.
• W2000535235 cites W2110879982 @default.
• W2000535235 cites W2131713441 @default.
• W2000535235 cites W2135942966 @default.
• W2000535235 cites W2137181647 @default.
• W2000535235 cites W2143198897 @default.
• W2000535235 cites W2145496597 @default.
• W2000535235 cites W2163161835 @default.
• W2000535235 cites W2264932050 @default.
• W2000535235 cites W2473340042 @default.
• W2000535235 cites W2951178388 @default.
• W2000535235 cites W4285719527 @default.
• W2000535235 cites W83715629 @default.
• W2000535235 doi "https://doi.org/10.1038/sj.bjp.0705929" @default.
• W2000535235 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1575425" @default.
• W2000535235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15466450" @default.
• W2000535235 hasPublicationYear "2004" @default.
• W2000535235 type Work @default.
• W2000535235 sameAs 2000535235 @default.
• W2000535235 citedByCount "107" @default.
• W2000535235 countsByYear W20005352352012 @default.
• W2000535235 countsByYear W20005352352013 @default.
• W2000535235 countsByYear W20005352352014 @default.
• W2000535235 countsByYear W20005352352015 @default.
• W2000535235 countsByYear W20005352352016 @default.
• W2000535235 countsByYear W20005352352017 @default.
• W2000535235 countsByYear W20005352352018 @default.
• W2000535235 countsByYear W20005352352020 @default.
• W2000535235 countsByYear W20005352352021 @default.
• W2000535235 countsByYear W20005352352022 @default.
• W2000535235 countsByYear W20005352352023 @default.
• W2000535235 crossrefType "journal-article" @default.
• W2000535235 hasAuthorship W2000535235A5008117910 @default.
• W2000535235 hasAuthorship W2000535235A5010423079 @default.
• W2000535235 hasAuthorship W2000535235A5013867167 @default.
• W2000535235 hasAuthorship W2000535235A5018967713 @default.
• W2000535235 hasAuthorship W2000535235A5027330002 @default.
• W2000535235 hasAuthorship W2000535235A5041298768 @default.
• W2000535235 hasAuthorship W2000535235A5057624684 @default.
• W2000535235 hasAuthorship W2000535235A5062317656 @default.
• W2000535235 hasAuthorship W2000535235A5066889736 @default.
• W2000535235 hasAuthorship W2000535235A5083508865 @default.
• W2000535235 hasAuthorship W2000535235A5091808052 @default.
• W2000535235 hasBestOaLocation W20005352352 @default.
• W2000535235 hasConcept C126322002 @default.
• W2000535235 hasConcept C134018914 @default.
• W2000535235 hasConcept C170493617 @default.
• W2000535235 hasConcept C174510640 @default.
• W2000535235 hasConcept C185592680 @default.
• W2000535235 hasConcept C192096249 @default.
• W2000535235 hasConcept C2775864247 @default.
• W2000535235 hasConcept C2776885963 @default.
• W2000535235 hasConcept C2778122271 @default.

• next